Global Pancreatic Cancer Diagnostic Market Size, Trends, By Treatment (Surgery, Chemotherapy, Radiation Therapy, and Targeted Therapy), By Test (Imaging Test, Biopsy, and Blood test), By End User (Hospitals, Clinics, and Research Institutes), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa): Global Opportunity Analysis and Industry Forecast, 2023-2030.
Global Pancreatic Cancer Diagnostic Market
The Global Pancreatic Cancer Diagnostic Market was valued at US$ 2,731.17 Mn in 2022, estimated to reach US$ 6,846.81 Mn by 2030, with a CAGR of 9.84% from 2023-2030.
Pancreatic cancer arises when an area of the pancreas experiences unchecked cell growth. Abdominal discomfort and jaundice are typical symptoms, however, they could not appear until later in the course of the illness. The pancreas is located behind the stomach, next to the gallbladder. It is made composed of glands that create insulin and other hormones and enzymes. Rarely is pancreatic cancer found in the early stages, when it is most curable. This is because symptoms frequently do not appear until the disease has spread to other organs. The severity of the condition affects the options for treating pancreatic cancer. Options for treatment include surgery, chemotherapy, radiation therapy, or a combination of these.
Market Drivers
The rising death rate and rising disease prevalence, as well as improvements in diagnostic technology and public awareness of the importance of early disease diagnosis. There is a growing need to create novel automated and precise diagnostic methods to lessen the burden of disease globally. In the upcoming years, the market expansion is anticipated to be fueled by research into new biomarker identification, the development of artificial intelligence (AI), and the use of nanoparticles for pancreatic cancer. Additionally, the use of AI in imaging, pathology, and biomarker tests will increase the use of diagnostic tests for pancreatic cancer.
Market Restraints
The high cost of the treatment will impede the market's rate of expansion. The market for pancreatic cancer treatments will face difficulties due to a shortage of qualified specialists and a lack of healthcare infrastructure in underdeveloped nations. Additionally, during the projected period, rigorous regulatory rules and a lack of public awareness would limit and restrict the market's rate of growth.
COVID 19 Impact
The World Health Organisation (WHO) has declared a public health emergency as a result of the COVID-19 virus's widespread distribution to almost every nation on earth. A brand-new coronavirus called COVID-19 has been determined to be the cause of cases of pneumonia. This virus soon spread over the world and claimed numerous lives. The World Health Organisation (WHO) declared COVID-19 a global pandemic in March 2020 and advised strict steps to stop the disease's spread. Since then, the pandemic has slowed down healthcare industry growth and messed up the supply chain. To stop the spread of COVID-19, governments in numerous countries had also implemented nationwide lockdowns. Similar issues prevented healthcare organizations around the world from carrying out their supply chain operations.
Market Segmentation
The scope of the Global Pancreatic Cancer Diagnostic Market covers segmentation based on Treatment, Test, End User, and Region.
Based on Treatment, the market is classified into Surgery, Chemotherapy, Radiation Therapy, and Targeted Therapy.
Based on Test, the market is divided into Imaging Test, Biopsy, and Blood Test.
Based on End User, the market is bifurcated into Hospitals, Clinics, and Research Institutes.
Regional Analysis
The Global Pancreatic Cancer Diagnostic Market is segmented into 5 main regions, namely, North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
North America is anticipated to hold the major market share during the forecast period. Pancreatic cancer cases are increasing, the elderly population is growing, and there are treatments for advanced diagnostics available. Generous reimbursement practices and high healthcare costs. For instance, in 2023, the American Cancer Society predicts that 64,050 people will receive a pancreatic cancer tumor diagnosis.
The Asia Pacific is predicted to grow at the quickest rate over the projection period due to a growing patient base, an increase in research activities to produce novel testing solutions, and improvements in healthcare policies in the area. Due to an increase in pancreatic cancer cases and the availability of cutting-edge treatment options, the market in the Asia-Pacific region is anticipated to rise at a healthy rate.
Key Players
Siemens Healthcare GmbH, FUJIFILM Corporation, Laboratory Corporation of America Holdings, Abbott, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Amgen Inc., Achieve Life Sciences, Inc., Infinity Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited
Market Taxonomy
By Treatment
• Surgery
• Chemotherapy
• Radiation Therapy
• Targeted Therapy
By Test
• Imaging Test
• Biopsy
• Blood test
By End User
• Hospitals
• Clinics
• Research Institutes
By Region
• North America
o U.S.
o Canada
o Mexico
• Latin America
o Brazil
o Argentina
o Colombia
o Peru
o Chile
o Venezuela
o Rest of Latin America
• Europe
o Germany
o France
o UK
o Russia
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o New Zealand
o Singapore
o Malaysia
o Rest of Asia Pacific
• Middle East & Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest Middle East & Africa
Key Questions Addressed by the Report
• What are the Key Opportunities in Global Bonsai Market?
• What will be the growth rate from 2023 to 2030?
• Which segment/region will have the highest growth?
• What are the factors that will impact/drive the Market?
• What is the competitive Landscape in the Industry?
• What is the role of key players in the value chain?
Global Pancreatic Cancer Diagnostic Market
1 Introduction
1.1 Objective of the Study
1.2 Market Definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Pancreatic Cancer Diagnostic Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn.
4.2.6 Post covid-19 world Supply& Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Pancreatic Cancer Diagnostic Market, By Treatment
5.1 Y-o-Y Growth Comparison, By Test and Services
5.2 Global Pancreatic Cancer Diagnostic Market Share Analysis, By Treatment
5.3 Global Pancreatic Cancer Diagnostic Market Size and Forecast, By Treatment
5.3.1 Surgery
5.3.2 Chemotherapy
5.3.3 Radiation Therapy
5.3.4 Targeted Therapy
6 Global Pancreatic Cancer Diagnostic Market, By Test
6.1 Y-o-Y Growth Comparison, By Test
6.2 Global Pancreatic Cancer Diagnostic Market Share Analysis, By Test
6.3 Global Pancreatic Cancer Diagnostic Market Size and Forecast, By Test
6.3.1 Imaging Test
6.3.2 Biopsy
6.3.4 Blood test
7 Global Pancreatic Cancer Diagnostic Market, By End User
7.1 Y-o-Y Growth Comparison, By End User
7.2 Global Pancreatic Cancer Diagnostic Market Share Analysis, By End User
7.3 Global Pancreatic Cancer Diagnostic Market Size and Forecast, By End User
7.3.1 Hospitals
7.2.2 Clinics
7.2.3 Research Institutes
8 Global Pancreatic Cancer Diagnostic Market, By Region
8.1 Global Pancreatic Cancer Diagnostic Market Share Analysis, By Region
8.2 Global Pancreatic Cancer Diagnostic Market Size and Forecast, By Region
8.3 Global Pancreatic Cancer Diagnostic Market Trends and Forecast, By Region
9 North America Pancreatic Cancer Diagnostic Market Analysis and Forecast (2023-2030)
9.1 Introduction
9.2 North America Pancreatic Cancer Diagnostic Market Share Analysis, By Treatment
9.3 North America Pancreatic Cancer Diagnostic Market Size and Forecast, By Test
9.4 North America Pancreatic Cancer Diagnostic Market Size and Forecast, By End User
9.5 North America Pancreatic Cancer Diagnostic Market Size and Forecast, By Country
9.5.1 U.S.
9.5.1.1 Market Size and Forecast, By Treatment
9.5.1.2 Market Size and Forecast, By Test
9.5.1.3 Market Size and Forecast, By End User
9.5.2 Canada
9.5.2.1 Market Size and Forecast, By Treatment
9.5.2.2 Market Size and Forecast, By Test
9.5.2.3 Market Size and Forecast, By End User
9.5.3 Mexico
9.5.3.1 Market Size and Forecast, By Treatment
9.5.3.2 Market Size and Forecast, By Test
9.5.3.3 Market Size and Forecast, By End User
10 Europe Pancreatic Cancer Diagnostic Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 Europe Pancreatic Cancer Diagnostic Market Share Analysis, By Treatment
10.3 Europe Pancreatic Cancer Diagnostic Market Size and Forecast, By Test
10.4 Europe Pancreatic Cancer Diagnostic Market Size and Forecast, By End User
10.5 Europe Pancreatic Cancer Diagnostic Market Size and Forecast, By Country
10.5.1 Germany
10.5.1.1 Market Size and Forecast, By Treatment
10.5.1.2 Market Size and Forecast, By Test
10.5.1.3 Market Size and Forecast, By End User
10.5.2 France
10.5.2.1 Market Size and Forecast, By Treatment
10.5.2.2 Market Size and Forecast, By Test
10.5.2.3 Market Size and Forecast, By End User
10.5.3 UK
10.5.3.1 Market Size and Forecast, By Treatment
10.5.3.2 Market Size and Forecast, By Test
10.5.3.3 Market Size and Forecast, By End User
10.5.4. Russia
10.5.4.1 Market Size and Forecast, By Treatment
10.5.4.2 Market Size and Forecast, By Test
10.5.4.3 Market Size and Forecast, By End User
10.5.5. Italy
10.5.5.1 Market Size and Forecast, By Treatment
10.5.5.2 Market Size and Forecast, By Test
10.5.5.3 Market Size and Forecast, By End User
10.5.6 Spain
10.5.6.1 Market Size and Forecast, By Treatment
10.5.6.2 Market Size and Forecast, By Test
10.5.6.3 Market Size and Forecast, By End User
10.5.7 Rest of Europe
10.5.7.1 Market Size and Forecast, By Treatment
10.5.7.2 Market Size and Forecast, By Test
10.5.7.3 Market Size and Forecast, By End User
11 Asia Pacific Pancreatic Cancer Diagnostic Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Asia Pacific Pancreatic Cancer Diagnostic Market Share Analysis, By Treatment
11.3 Asia Pacific Pancreatic Cancer Diagnostic Market Size and Forecast, By Test
11.4 Asia Pacific Pancreatic Cancer Diagnostic Market Size and Forecast, By End User
11.5 Asia Pacific Pancreatic Cancer Diagnostic Market Size and Forecast, By Country
11.5.1 China
11.5.1.1 Market Size and Forecast, By Treatment
11.5.1.2 Market Size and Forecast, By Test
11.5.1.3 Market Size and Forecast, By End User
11.5.2 Japan
11.5.2.1 Market Size and Forecast, By Treatment
11.5.2.2 Market Size and Forecast, By Test
11.5.2.3 Market Size and Forecast, By End User
11.5.3 India
11.5.3.1 Market Size and Forecast, By Treatment
11.5.3.2 Market Size and Forecast, By Test
11.5.3.3 Market Size and Forecast, By End User
11.5.4. South Korea
11.5.4.1 Market Size and Forecast, By Treatment
11.5.4.2 Market Size and Forecast, By Test
11.5.4.3 Market Size and Forecast, By End User
11.5.5. Australia
11.5.5.1 Market Size and Forecast, By Test and Services
11.5.5.2 Market Size and Forecast, By Test
11.5.5.3 Market Size and Forecast, By End User
11.5.6. New Zealand
11.5.6.1 Market Size and Forecast, By Treatment
11.5.6.2 Market Size and Forecast, By Test
11.5.6.3 Market Size and Forecast, By End User
11.5.7 Singapore
11.5.7.1 Market Size and Forecast, By Treatment
11.5.7.2 Market Size and Forecast, By Test
11.5.7.3 Market Size and Forecast, By End User
11.5.8. Malaysia
11.5.8.1 Market Size and Forecast, By Test and Services
11.5.8.2 Market Size and Forecast, By Test
11.5.8.3 Market Size and Forecast, By End User
11.5.9 Rest of Asia
11.5.9.1 Market Size and Forecast, By Treatment
11.5.9.2 Market Size and Forecast, By Test
11.5.9.3 Market Size and Forecast, By End User
12 Latin America Pancreatic Cancer Diagnostic Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Latin America Pancreatic Cancer Diagnostic Market Share Analysis, By Treatment
12.3 Latin America Pancreatic Cancer Diagnostic Market Size and Forecast, By Test
12.4 Latin America Pancreatic Cancer Diagnostic Market Size and Forecast, By End User
12.5 Latin America Pancreatic Cancer Diagnostic Market Size and Forecast, By Country
12.5.1 Brazil
12.5.1.1 Market Size and Forecast, By Treatment
12.5.1.2 Market Size and Forecast, By Test
12.5.1.3 Market Size and Forecast, By End User
12.5.2 Argentina
12.5.2.1 Market Size and Forecast, By Treatment
12.5.2.2 Market Size and Forecast, By Test
12.5.2.3 Market Size and Forecast, By End User
12.5.3. Colombia
12.5.3.1 Market Size and Forecast, By Treatment
12.5.3.2 Market Size and Forecast, By Test
12.5.3.3 Market Size and Forecast, By End User
12.5.4. Peru
12.5.4.1 Market Size and Forecast, By Treatment
12.5.4.2 Market Size and Forecast, By Test
12.5.4.3 Market Size and Forecast, By End User
12.5.5 Chile
12.5.5.1 Market Size and Forecast, By Treatment
12.5.5.2 Market Size and Forecast, By Test
12.5.5.3 Market Size and Forecast, By End User
12.5.6 Venezuela
12.5.6.1 Market Size and Forecast, By Treatment
12.5.6.2 Market Size and Forecast, By Test
12.5.6.3 Market Size and Forecast, By End User
12.5.7 Rest of Latin America
12.5.7.1 Market Size and Forecast, By Treatment
12.5.7.2 Market Size and Forecast, By Test
12.5.7.3 Market Size and Forecast, By End User
13 Middle East Pancreatic Cancer Diagnostic Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Middle East Pancreatic Cancer Diagnostic Market Share Analysis, By Treatment
13.3 Middle East Pancreatic Cancer Diagnostic Market Size and Forecast, By Test
13.4 Middle East Pancreatic Cancer Diagnostic Market Size and Forecast, By End User
13.5 Middle East Pancreatic Cancer Diagnostic Market Size and Forecast, By Country
13.5.1 Saudi Arabia
13.5.1.1 Market Size and Forecast, By Treatment
13.5.1.2 Market Size and Forecast, By Test
13.5.1.3 Market Size and Forecast, By End User
13.5.2 UAE
13.5.2.1 Market Size and Forecast, By Treatment
13.5.2.2 Market Size and Forecast, By Test
13.5.2.3 Market Size and Forecast, By End User
13.5.3 Egypt
13.5.3.1 Market Size and Forecast, By Treatment
13.5.3.2 Market Size and Forecast, By Test
13.5.3.3 Market Size and Forecast, By End User
13.5.4 Kuwait
13.5.4.1 Market Size and Forecast, By Treatment
13.5.4.2 Market Size and Forecast, By Test
13.5.4.3 Market Size and Forecast, By End User
13.5.5 South Africa
13.5.5.1 Market Size and Forecast, By Treatment
13.5.5.2 Market Size and Forecast, By Test
13.5.5.3 Market Size and Forecast, By End User
13.5.5 Rest of Middle East & Africa
13.5.6.1 Market Size and Forecast, By Treatment
13.5.6.2 Market Size and Forecast, By Test
13.5.6.3 Market Size and Forecast, By End User
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 Siemens Healthcare GmbH
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2 FUJIFILM Corporation
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3 Laboratory Corporation of America Holdings
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 Abbott
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Agilent Technologies, Inc.
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Thermo Fisher Scientific Inc.
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Amgen Inc.
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Achieve Life Sciences, Inc.
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 Infinity Pharmaceuticals Inc.
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 Takeda Pharmaceutical Company Limited
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies
